ACRS
Aclaris Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$631.28M
P/E Ratio
—
EPS
$-0.56
Beta
0.78
52W High
$5.15
52W Low
$1.27
50-Day MA
$4.18
200-Day MA
$3.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
-0.13
About Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a line of novel small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company is headquartered in Wayne, Pennsylvania.
Fundamentals
| Revenue (TTM) | $8.37M |
| Gross Profit (TTM) | $-55.91M |
| EBITDA | $-78.47M |
| Operating Margin | -1112.00% |
| Return on Equity | -48.40% |
| Return on Assets | -24.70% |
| Revenue/Share (TTM) | $0.07 |
| Book Value | $1.03 |
| Price-to-Book | 4.39 |
| Price-to-Sales (TTM) | 75.45 |
| EV/Revenue | 62.85 |
| EV/EBITDA | 0.28 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 37.20% |
| Shares Outstanding | $139.66M |
| Float | $113.21M |
| % Insiders | 2.23% |
| % Institutions | 79.65% |
Historical Volatility
HV 10-Day
51.54%
HV 20-Day
52.30%
HV 30-Day
54.00%
HV 60-Day
69.89%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($9.67 target)
1
Strong Buy7
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026